Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05919238 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma

Name: Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma — clinical trial record (NCT05919238)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorImpact Biotech Ltd

Started2024-05-15

View on ClinicalTrials.gov ↗

Record status

This record was last updated August 19, 2026 (before its estimated August 30, 2026 completion). Its status may not reflect the trial's current state.

This is a prospective, multicenter, non-randomized, open label light dose escalation phase I trial to evaluate the safety and preliminary efficacy of Padeliporfin vascular targeted photodynamic therapy (VTP) applied via endovascular fiber placement within a dilatation catheter, through the target artery(superior mesenteric artery (SMA), celiac artery (CA) or common hepatic artery (CHA)). The investigators will evaluate safety and preliminary efficacy of Padeliporfin VTP administered endovascularly using light dose escalation.

Amendment history 1 change detected by DataLookout

2026-08-20

Primary completion pushed: 2026-05-30 → 2026-08-30

Trial Details

NCT Number	NCT05919238
Lead Sponsor	Impact Biotech Ltd
Conditions	Locally Advanced Unresectable Pancreatic Adenocarcinoma
Enrollment	30 participants
Start Date	2024-05-15
Primary Completion	2026-08-30 (estimated)
Study Completion	2026-10-30 (estimated)
Updated on ClinicalTrials.gov	2026-08-19